Summary: 

The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use.

Description of Technology: 

Chimeric antigen receptor (CAR)-T cell therapy has been successful in leukemia but its use for the treatment of solid tumors has been challenging.  CD276, also known as B7-H3, is a surface tumor marker highly expressed in the vasculature and surface of solid tumors. This strong expression in both areas of solid tumors makes CD276 a promising target for cancer therapies such as CARs.

This technology comprises of a panel of five fully human antibodies (Y868, Y422, Y111, Y117, and YE5) against CD276 that can be incorporated into immunotherapies.  The CARs generated using these antibodies were evaluated and compared to other known CD276-targeting CARs in development.  One of the CARs showed a more durable anti-tumor response superior to all others tested, including those known in the literature.  CARs generated from this set are effective against Panc1 pancreatic tumor models. One CAR in particular showing high efficacy in the HPAC pancreatic tumor model which was resistant to all other CARs.  In addition to CARs, the antibodies developed under this invention could potentially be used in other antibody-based therapeutics targeting CD276 including other cell therapies such as CAR NK-cell therapies.   

Potential Commercial Applications: 

CAR T-Cell therapy for treatment of pancreatic cancer
CAR T-Cell or NK cell therapy for treatment of several solid tumors 
Antibody based therapeutics such as antibody drug conjugates (ADCs) for the treatment of solid tumors 

Competitive Advantages:

High efficacy against tumors resistant to other CARs
CD276 target is highly expressed on many solid tumor types
Fully human antibody potentially less immunogenic than those derived from mouse